Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Sarcoidosis

  • Author: Nader Kamangar, MD, FACP, FCCP, FCCM; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
 
Updated: May 31, 2016
 

Practice Essentials

Sarcoidosis is a multisystem inflammatory disease of unknown etiology that manifests as noncaseating granulomas, predominantly in the lungs and intrathoracic lymph nodes. The age-adjusted incidence is 11 cases per 100,000 population in whites but 34 cases per 100,000 population in African Americans. 

Signs and symptoms

The presentation in sarcoidosis varies with the extent and severity of organ involvement, as follows:

  • Asymptomatic (incidentally detected on chest imaging): Approximately 5% of cases
  • Systemic complaints (fever, anorexia): 45% of cases
  • Pulmonary complaints (dyspnea on exertion, cough, chest pain, and hemoptysis [rare]): 50% of cases
  • Löfgren syndrome (fever, bilateral hilar lymphadenopathy, and polyarthralgias): Common in Scandinavian patients, but uncommon in African-American and Japanese patients

Pulmonary findings on physical examination are as follows:

  • Usually normal
  • Crackles may be audible
  • Exertional oxygen desaturation may be present

Dermatologic manifestations may include the following:

  • Erythema nodosum
  • A lower-extremity panniculitis with painful, erythematous nodules (often with Löfgren syndrome)
  • Lupus pernio (the most specific associated cutaneous lesion)
  • Violaceous rash on the cheeks or nose (common)
  • Maculopapular plaques (uncommon)

Ocular involvement, which may lead to blindness if untreated, may manifest as follows:

  • Anterior or posterior granulomatous uveitis (most frequent)
  • Conjunctival lesions and scleral plaques

Other possible manifestations are as follows:

  • Osseous involvement
  • Heart failure from cardiomyopathy (rare)
  • Heart block and sudden death
  • Lymphocytic meningitis (rare)
  • Cranial nerve palsies and hypothalamic/pituitary dysfunction (rare)

See Clinical Presentation for more detail.

Diagnosis

Imaging studies for sarcoidosis are as follows:

  • Chest radiography: Central to the evaluation
  • Routine chest computed tomography (CT): Adds little to radiography
  • High-resolution CT (HRCT) scanning of the chest: May be helpful; identifies active alveolitis versus fibrosis, and findings correlate with biopsy yield
  • Gallium scans: Used infrequently; has low sensitivity and specificity, but may be helpful when the clinical picture remains confusing despite histologic evidence of noncaseating granulomas (eg, differentiating chronic hypersensitivity pneumonitis from sarcoidosis)

Staging of sarcoidosis is as follows:

  • Stage 0: Normal chest radiographic findings
  • Stage I: Bilateral hilar lymphadenopathy
  • Stage II: Bilateral hilar lymphadenopathy and infiltrates
  • Stage III: Infiltrates alone
  • Stage IV: Fibrosis

Pulmonary function tests and a carbon monoxide diffusion capacity test of the lungs for carbon monoxide (DLCO) are used routinely in evaluation and follow-up. Possible findings are as follows:

  • An isolated decrease in DLCO is the most common abnormality
  • A restrictive pattern is seen in patients with more advanced pulmonary disease
  • Approximately 15-20% of patients have obstruction

Cardiopulmonary exercise testing is a sensitive test for identifying and quantifying the extent of pulmonary involvement. Cardiopulmonary exercise testing also may suggest cardiac involvement that otherwise is not evident. Impaired heart rate recovery during the first minute following exercise has been shown to be an independent predictor for cardiovascular and all-cause mortality,[1] and it may identify patients who are at high risk for ventricular arrhythmias and sudden death.[2]

All patients with sarcoidosis should have an annual electrocardiogram. Patients who report palpitations should have a thorough evaluation with at least Holter monitoring.

Diagnosis requires biopsy in most cases. Endobronchial biopsy via bronchoscopy is often done. The yield is high; results may be positive even in patients with normal chest radiographs. The central histologic finding is the presence of noncaseating granulomas with special stains negative for fungus and mycobacteria.

Routine laboratory evaluation is often unrevealing, but possible abnormalities include the following:

  • Hypercalcemia (about 10-13% of patients)
  • Hypercalciuria (about a third of patients)
  • Elevated alkaline phosphatase level
  • Elevated angiotensin-converting enzyme (ACE) levels

See Workup for more detail.

Management

Nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated for the treatment of arthralgias and other rheumatic complaints. Patients with stage I sarcoidosis often require only occasional treatment with NSAIDs.

Treatment in patients with pulmonary involvement is as follows:

  • Asymptomatic patients may not require treatment
  • In patients with minimal symptoms, serial reevaluation is prudent
  • Treatment is indicated for patients with significant respiratory symptoms
  • Corticosteroids can produce small improvements in the functional vital capacity and in the radiographic appearance in patients with more severe stage II and III disease

For extrapulmonary sarcoidosis involving such critical organs as the heart, liver, eyes, kidneys, or central nervous system, corticosteroid therapy is indicated. Topical corticosteroids are effective for ocular disease. For pulmonary disease, prednisone is generally given daily and then tapered over a 6-month course. High-dose inhaled corticosteroids may be an option, particularly in patients with endobronchial disease

Common indications for noncorticosteroid agents include the following:

  • Steroid-resistant disease
  • Intolerable adverse effects of steroids
  • Patient desire not to take corticosteroids

Noncorticosteroid agents include the following:

  • Methotrexate (MTX) has been a successful alternative to prednisone
  • Chloroquine and hydroxychloroquine have been used for cutaneous lesions, hypercalcemia, neurologic sarcoidosis, and bone lesions
  • Chloroquine has been found effective for acute and maintenance treatment of chronic pulmonary sarcoidosis [3, 4]
  • Cyclophosphamide has been rarely used with modest success as a steroid-sparing treatment in patients with refractory sarcoidosis [5, 6]
  • Azathioprine is best used as a steroid-sparing agent [7]
  • Chlorambucil may be beneficial in patients with progressive disease unresponsive to corticosteroids or when corticosteroids are contraindicated [8]
  • Cyclosporine may be of limited benefit in skin sarcoidosis or in progressive sarcoid resistant to conventional therapy [9]
  • Infliximab [10, 11] and thalidomide [12, 13] have been used for refractory sarcoidosis, particularly for cutaneous disease, as well as for the long-term management of extrapulmonary sarcoidosis [14]
  • Infliximab appears to be an effective treatment for patients with systemic manifestations such as lupus pernio, uveitis, hepatic sarcoidosis, and neurosarcoidosis

For patients with advanced pulmonary fibrosis from sarcoidosis, lung transplantation remains the only hope for long-term survival. Indications for transplantation include either or both of the following[15] :

  • Forced vital capacity below 50% predicted
  • Forced expiratory volume in 1 second below 40% predicted

See Treatment and Medication for more detail.

Next

Background

Sarcoidosis is a multisystem inflammatory disease of unknown etiology that predominantly affects the lungs and intrathoracic lymph nodes. Sarcoidosis is manifested by the presence of noncaseating granulomas (NCGs) in affected organ tissues. It is characterized by a seemingly exaggerated immune response against a difficult–to-discern antigen.[16]

Related Medscape articles include Acute Complications of Sarcoidosis, Dermatologic Manifestations of Sarcoidosis, and Ophthalmic Manifestations of Sarcoidosis.

Previous
Next

Pathophysiology

T cells play a central role in the development of sarcoidosis, as they likely propagate an excessive cellular immune reaction. For example, there is an accumulation of CD4 cells accompanied by the release of interleukin (IL)–2 at sites of disease activity. This may manifest clinically by an inverted CD4/CD8 ratio. Pulmonary sarcoidosis is frequently characterized by a CD4+/CD8+ ratio of at least 3.5 in bronchoalveolar lavage fluid (BALF), although up to 40% of the cases present a normal or even decreased ratio, thus limiting its diagnostic value.[17] Increased production of TH1 cytokines, such as interferon, is also a feature.

Moreover, both tumor necrosis factor (TNF) and TNF receptors are increased in this disease. The importance of TNF in propagating inflammation in sarcoidosis has been demonstrated by the efficacy of anti-TNF agents, such as pentoxifylline[18] and infliximab,[10, 11] in treating this disease.

In addition to T cells, B cells also play a role. There is evidence of B cell hyperreactivity with immunoglobulin production.

Soluble HLA class I antigens levels in serum and BALF are higher in patients with sarcoidosis. These levels tend to be significantly higher in active than in inactive stages and correlate with angiotensin-converting enzyme (ACE) levels.[19]

Active sarcoidosis has also been associated with plasmatic hypergammaglobulinemia.[20] B-cell accumulation has been shown in pulmonary lesions, and a beneficial effect with anti-CD20 monoclonal antibody therapy has been reported in select patients.

Glycoprotein KL-6 and surfactant protein D (SP-D) derived from alveolar type II cells and bronchiolar epithelial cells are significantly increased in pulmonary sarcoidosis and correlate with the percentage of lymphocytes in BALF, reflecting an inflammatory response in sarcoidosis. However, there is no significant correlation between KL-6 or SP-D levels and chest radiography findings, ACE levels, or CD4/CD8 ratio in BALF.[21] KL-6 has been shown to be predictive of increased pulmonary parenchymal infiltration.[22]

A study by Facco et al suggests that Th17 cells may play a role in the pathogenesis and progression of sarcoidosis; these cells were noted to be present in the blood, BALF samples, and lung tissue from patients with sarcoidosis, particularly in those with the active form of the disease.[23]

Previous
Next

Epidemiology

Frequency

United States

Incidence ranges from 5-40 cases per 100,000 population. The age-adjusted incidence for whites is 11 cases per 100,000 population. The incidence is considerably higher for African Americans, at 34 cases per 100,000 population. The prevalence is 10 times greater for African Americans than for whites. Approximately 20% of patients who are African American reported an affected family member, while only 5% of whites in the United States who have sarcoidosis state they have family members also diagnosed with sarcoidosis. African Americans seem to experience more severe and chronic disease.[24] In African Americans, siblings and parents of sarcoidosis cases have about a 2.5-fold increased risk for developing the disease.

Working on the World Trade Center (WTC) debris pile after the September 11, 2001 terrorist attacks was associated with sarcoidosis[25] (odds ratio, 9.1; 95% confidence interval, 1.1-74.0), but WTC dust cloud exposure was not (odds ratio, 1.0; 95% confidence interval, 0.4-2.8).

International

Incidence is 20 cases per 100,000 population in Sweden and 1.3 cases per 100,000 population in Japan. Sarcoidosis occurs in China, Africa, India, and other developing countries. Although its incidence may be low, the disease remains hidden and often is misdiagnosed as tuberculosis.

Race

See Frequency, United States and Mortality/Morbidity.

Sex

Male-to-female ratio is approximately 1:2. Morbidity, mortality, and extrapulmonary involvement are higher in affected females.[26]

Age

Incidence peaks in persons aged 25-35 years. A second peak occurs for women aged 45-65 years.

Previous
Next

Prognosis

Many patients do not require therapy, and their conditions spontaneously improve. Markers for a poor prognosis include advanced chest radiography stage, extrapulmonary disease (predominantly cardiac and neurologic), and evidence of pulmonary hypertension. Multiple studies have demonstrated that the most important marker for prognosis is the initial chest radiography stage (see Table 2 below).

In one study of patients with radiographic stage IV sarcoidosis, during an average follow-up of 7 years, pulmonary hypertension was observed in 30% of cases. Long-term oxygen therapy was required in 12%. Survival was 84% at 10 yrs. Cause of death in 11% patients included refractory pulmonary hypertension, acute and chronic respiratory insufficiency, and heart sarcoidosis. Seventy-five percent of fatalities are directly attributable to respiratory causes.[27]

Table 1. Prognosis (Open Table in a new window)

Stage Remission (%) Asymptomatic at 5 y (%) Chest Radiograph Clearing (%) Mortality (%)
Stage I 60-90 95 54 0
Stage II 40-70 58 31 11
Stage III 10-20 25 10 18
Stage IV 0 N/A 0 N/A

Data regarding mortality from sarcoidosis are scant. In the United States, deaths tend to result from the complications of end-stage lung disease (eg, respiratory failure, right heart failure).

Functional impairment occurs in only 15-20% of patients and often resolves spontaneously. The overall mortality rate is less than 5% for untreated patients.

The likelihood of regression for pulmonary disease correlates with the extent of parenchymal disease, as noted by chest radiography stage.

According to a study by Swigris et al, the rate of sarcoidosis-related mortality in the United States appears to have increased significantly from 1988-2007, particularly in black females aged 55 years or older. This study also confirmed findings from prior reports, indicating that the underlying cause of death in most patients with sarcoidosis was the disease itself.[28]

Previous
 
 
Contributor Information and Disclosures
Author

Nader Kamangar, MD, FACP, FCCP, FCCM Professor of Clinical Medicine, University of California, Los Angeles, David Geffen School of Medicine; Chief, Division of Pulmonary and Critical Care Medicine, Vice-Chair, Department of Medicine, Olive View-UCLA Medical Center

Nader Kamangar, MD, FACP, FCCP, FCCM is a member of the following medical societies: Academy of Persian Physicians, American Academy of Sleep Medicine, American Association for Bronchology and Interventional Pulmonology, American College of Chest Physicians, American College of Critical Care Medicine, American College of Physicians, American Lung Association, American Medical Association, American Thoracic Society, Association of Pulmonary and Critical Care Medicine Program Directors, Association of Specialty Professors, California Sleep Society, California Thoracic Society, Clerkship Directors in Internal Medicine, Society of Critical Care Medicine, Trudeau Society of Los Angeles, World Association for Bronchology and Interventional Pulmonology

Disclosure: Nothing to disclose.

Coauthor(s)

Andrew F Shorr, MD, MPH Associate Professor of Medicine, Georgetown University School of Medicine, Associate Direfctor of Pulmonary and Critical Care, Washington Hospital Center

Andrew F Shorr, MD, MPH is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Thoracic Society

Disclosure: Nothing to disclose.

Payam Rohani, MD Resident Physician, Department of Internal Medicine, Olive View-UCLA Medical Center

Payam Rohani, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Zab Mosenifar, MD, FACP, FCCP Geri and Richard Brawerman Chair in Pulmonary and Critical Care Medicine, Professor and Executive Vice Chairman, Department of Medicine, Medical Director, Women's Guild Lung Institute, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine

Zab Mosenifar, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society

Disclosure: Nothing to disclose.

Additional Contributors

Stephen P Peters, MD, PhD, FACP, FAAAAI, FCCP, FCPP Thomas H Davis Chair in Pulmonary Medicine, Chief, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Professor of Internal Medicine, Pediatrics, and Translational Science, Associate Director, Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine; Executive Director of the Respiratory Service Line, Wake Forest Baptist Medical Center

Stephen P Peters, MD, PhD, FACP, FAAAAI, FCCP, FCPP is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society, Sigma Xi

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Integrity CE, Merck<br/>Received income in an amount equal to or greater than $250 from: – Array Biopharma, AstraZeneca, Aerocrine, Airsonett AB, Boehringer-Ingelheim, Experts in Asthma, Gilead, GlaxoSmithKline, Merck, Novartis, Ono Pharmaceuticals, Pfizer, PPD Development, Quintiles, Sunovion, Saatchi & Saatichi, Targacept, TEVA, Theron.

References
  1. Arai Y, Saul JP, Albrecht P, Hartley LH, Lilly LS, Cohen RJ, et al. Modulation of cardiac autonomic activity during and immediately after exercise. Am J Physiol. 1989 Jan. 256(1 Pt 2):H132-41. [Medline].

  2. Shetler K, Marcus R, Froelicher VF, Vora S, Kalisetti D, Prakash M. Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol. 2001 Dec. 38(7):1980-7. [Medline].

  3. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999 Jul. 160(1):192-7. [Medline].

  4. Zic JA, Horowitz DH, Arzubiaga C, King LE Jr. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol. 1991 Jul. 127(7):1034-40. [Medline].

  5. Demeter SL. Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest. 1988 Jul. 94(1):202-3. [Medline].

  6. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003 Nov. 124(5):2023-6. [Medline].

  7. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999 Nov. 14(5):1117-22. [Medline].

  8. Kataria YP. Chlorambucil in sarcoidosis. Chest. 1980 Jul. 78(1):36-43. [Medline].

  9. York EL, Kovithavongs T, Man SF, Rebuck AS, Sproule BJ. Cyclosporine and chronic sarcoidosis. Chest. 1990 Oct. 98(4):1026-9. [Medline].

  10. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005 Mar. 127(3):1064-71. [Medline].

  11. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001 Jul 3. 135(1):27-31. [Medline].

  12. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest. 2002 Jul. 122(1):227-32. [Medline].

  13. Fazzi P, Manni E, Cristofani R, Cei G, Piazza S, Calabrese R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother. 2012 Jun. 66(4):300-7. [Medline].

  14. Russell E, Luk F, Manocha S, Ho T, O'Connor C, Hussain H. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum. 2013 Jan 16. [Medline].

  15. Nathan SD. Lung transplantation: disease-specific considerations for referral. Chest. 2005 Mar. 127(3):1006-16. [Medline].

  16. Ten Berge B, Kleinjan A, Muskens F, Hammad H, Hoogsteden HC, Hendriks RW, et al. Evidence for local dendritic cell activation in pulmonary sarcoidosis. Respir Res. 2012 Apr 18. 13:33. [Medline]. [Full Text].

  17. Mota PC, Morais A, Palmares C, Beltrao M, Melo N, Santos AC, et al. Diagnostic value of CD103 expression in bronchoalveolar lymphocytes in sarcoidosis. Respir Med. 2012 Jul. 106(7):1014-20. [Medline].

  18. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997 May. 155(5):1665-9. [Medline].

  19. Ogisu N, Sato S, Kawaguchi H, Sugiura Y, Mori T, Niimi T, et al. Elevated level of soluble HLA class I antigens in serum and bronchoalveolar lavage fluid in patients with sarcoidosis. Intern Med. 2001 Mar. 40(3):201-7. [Medline].

  20. Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest. 1981 Jan. 67(1):86-92. [Medline].

  21. Kunitake R, Kuwano K, Yoshida K, Maeyama T, Kawasaki M, Hagimoto N, et al. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration. 2001. 68(5):488-95. [Medline].

  22. Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010 Jun. 137(6):1391-7. [Medline].

  23. Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011 Feb. 66(2):144-50. [Medline].

  24. Cox CE, Davis-Allen A, Judson MA. Sarcoidosis. Med Clin North Am. 2005 Jul. 89(4):817-28. [Medline].

  25. Jordan HT, Stellman SD, Prezant D, Teirstein A, Osahan SS, Cone JE. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J Occup Environ Med. 2011 Sep. 53(9):966-74. [Medline].

  26. Krell W, Bourbonnais JM, Kapoor R, Samavati L. Effect of smoking and gender on pulmonary function and clinical features in sarcoidosis. Lung. 2012 Oct. 190(5):529-36. [Medline].

  27. Nardi A, Brillet PY, Letoumelin P, Girard F, Brauner M, Uzunhan Y, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. 2011 Dec. 38(6):1368-73. [Medline].

  28. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011 Jun 1. 183(11):1524-30. [Medline].

  29. Takase H, Shimizu K, Yamada Y, Hanada A, Takahashi H, Mochizuki M. Validation of international criteria for the diagnosis of ocular sarcoidosis proposed by the first international workshop on ocular sarcoidosis. Jpn J Ophthalmol. 2010 Nov. 54(6):529-36. [Medline].

  30. Kojima K, Maruyama K, Inaba T, Nagata K, Yasuhara T, Yoneda K, et al. The CD4/CD8 ratio in vitreous fluid is of high diagnostic value in sarcoidosis. Ophthalmology. 2012 Nov. 119(11):2386-92. [Medline].

  31. Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009 May-Jun. 17(3):160-9. [Medline].

  32. Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009 May-Jun. 17(3):160-9. [Medline].

  33. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm. 2012 Jun. 9(6):884-91. [Medline].

  34. Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011 Apr. 16(2):140-7. [Medline].

  35. Schuller JL, Olson MD, Zipse MM, Schneider PM, Aleong RG, Wienberger HD, et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol. 2011 Nov. 22(11):1243-8. [Medline].

  36. Yasutake H, Seino Y, Kashiwagi M, Honma H, Matsuzaki T, Takano T. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol. 2005 Jul 10. 102(2):259-68. [Medline].

  37. Bihan H, Christozova V, Dumas JL, Jomaa R, Valeyre D, Tazi A, et al. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine (Baltimore). 2007 Sep. 86(5):259-68. [Medline].

  38. Inui N, Murayama A, Sasaki S, Suda T, Chida K, Kato S, et al. Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med. 2001 Jun 15. 110(9):687-93. [Medline].

  39. Goracci A, Fagiolini A, Martinucci M, Calossi S, Rossi S, Santomauro T, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008 Sep-Oct. 30(5):441-5. [Medline].

  40. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008 May. 133(5):1189-95. [Medline].

  41. Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, Svendsen CB. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008 Oct. 63(10):894-6. [Medline].

  42. Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010 Jun. 137(6):1391-7. [Medline].

  43. Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010 Apr. 104(4):564-70. [Medline].

  44. Cremers J, Drent M, Driessen A, Nieman F, Wijnen P, Baughman R, et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol. 2012 Jan. 24(1):17-24. [Medline].

  45. Davies CW, Tasker AD, Padley SP, Davies RJ, Gleeson FV. Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol. 2000 Mar. 55(3):217-21. [Medline].

  46. Mostard RL, Voo S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011 Dec. 105(12):1917-24. [Medline].

  47. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007 Dec. 132(6):1949-53. [Medline].

  48. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008 Aug. 32(2):296-302. [Medline].

  49. Ardic I, Kaya MG, Yarlioglues M, Dogdu O, Buyukoglan H, Kalay N. Impaired heart rate recovery index in patients with sarcoidosis. Chest. 2011 Jan. 139(1):60-8. [Medline].

  50. Trisolini R, Tinelli C, Cancellieri A, Paioli D, Alifano M, Boaron M, et al. Transbronchial needle aspiration in sarcoidosis: yield and predictors of a positive aspirate. J Thorac Cardiovasc Surg. 2008 Apr. 135(4):837-42. [Medline].

  51. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 2001 Jul. 120(1):109-14. [Medline].

  52. Oki M, Saka H, Kitagawa C, Kogure Y, Murata N, Ichihara S, et al. Prospective study of endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes versus transbronchial lung biopsy of lung tissue for diagnosis of sarcoidosis. J Thorac Cardiovasc Surg. 2012 Jun. 143(6):1324-9. [Medline].

  53. Moodley YP, Dorasamy T, Venketasamy S, Naicker V, Lalloo UG. Correlation of CD4:CD8 ratio and tumour necrosis factor (TNF)alpha levels in induced sputum with bronchoalveolar lavage fluid in pulmonary sarcoidosis. Thorax. 2000 Aug. 55(8):696-9. [Medline]. [Full Text].

  54. Fireman E, Topilsky I, Greif J, Lerman Y, Schwarz Y, Man A, et al. Induced sputum compared to bronchoalveolar lavage for evaluating patients with sarcoidosis and non-granulomatous interstitial lung disease. Respir Med. 1999 Nov. 93(11):827-34. [Medline].

  55. McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci. 2010 Jan. 339(1):1-4. [Medline].

  56. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002 Jan. 121(1):24-31. [Medline].

  57. Baughman RP, Barney JB, O'Hare L, Lower EE. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016 Jan. 110:66-72. [Medline].

  58. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995 Apr 24. 155(8):846-51. [Medline].

  59. Callejas-Rubio JL, Lopez-Perez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag. 2008 Dec. 4(6):1305-13. [Medline]. [Full Text].

  60. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012 May. 250(5):713-20. [Medline]. [Full Text].

  61. Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-a inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012 Oct. 6(4):238-47. [Medline].

  62. Arcasoy SM, Christie JD, Pochettino A, Rosengard BR, Blumenthal NP, Bavaria JE, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001 Sep. 120(3):873-80. [Medline].

  63. Ramos-Casals M, Mana J, Nardi N, Brito-Zeron P, Xaubet A, Sanchez-Tapias JM, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore). 2005 Mar. 84(2):69-80. [Medline].

 
Previous
Next
 
Stage I sarcoidosis.
Stage II sarcoidosis.
Stage III sarcoidosis.
Table 1. Prognosis
Stage Remission (%) Asymptomatic at 5 y (%) Chest Radiograph Clearing (%) Mortality (%)
Stage I 60-90 95 54 0
Stage II 40-70 58 31 11
Stage III 10-20 25 10 18
Stage IV 0 N/A 0 N/A
Table 2. Results of Multicenter Trial Sponsored by the British Thoracic Society
Characteristics Group La Group Sb P
Dyspnea score (range 1-4) 0.24 0.47 NS
Fibrosis score (range 0-16) 0.83 1.47 NS
FEV1c (% predicted) 95.9 86.9 0.05
VCd (% predicted) 99.8 90.8 0.02
DLCOe (% predicted) 84.3 77.7 NS
Weight gain (kg) +3.26 +0.99 0.02
a Long-term steroids.



b Short bursts of steroids.



c Forced expiratory volume in 1 second.



d Ventilatory capacity.



e Diffusing capacity of lung for carbon monoxide.



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.